MedPath

Adverse Events of Hepatic Anti-Fibrotic Agents in Phase 3 and Above Clinical Trials

A study analyzing adverse drug reactions (ADRs) associated with hepatic anti-fibrotic agents in phase 3 and above clinical trials, using data from the WHO-VigiAccess database, highlights the challenges in treating liver fibrosis. The research identifies significant ADRs linked to specific agents and emphasizes the need for optimized therapeutic strategies.

Liver fibrosis, a pathological response to chronic liver injuries, currently lacks FDA-approved pharmacotherapy. Despite advances in understanding hepatic fibrogenesis and the development of promising anti-fibrotic agents, adverse drug reactions (ADRs) pose significant challenges to their efficacy and clinical applicability. This study focuses on assessing ADRs associated with anti-fibrotic agents, utilizing data from the World Health Organization (WHO) VigiAccess database.
Methods: The research involved a detailed search on ClinicalTrial.gov to identify phase 3 or 4 clinical trials of hepatic anti-fibrotic agents. ADR reports were retrieved from the WHO-VigiAccess database, with data analyzed based on demographic characteristics, geographic distribution, and System Organ Classes (SOCs). Descriptive analysis identified the most frequently reported ADRs, while disproportionality analysis, measured by reporting odd ratio (ROR) and proportional report ratio (PRR), evaluated ADRs related to gastrointestinal disorders.
Results: Five hepatic anti-fibrotic agents—empagliflozin, liraglutide, candesartan, obeticholic acid, and resmetirom—were identified. Analysis of 130,567 ADR reports revealed that empagliflozin, liraglutide, and candesartan were associated with significantly higher ADRs. The most frequently reported SOCs included gastrointestinal disorders (29.44%), general disorders (24.12%), and nervous system disorders (14.42%). Notably, liraglutide demonstrated a higher risk of adverse reactions.
This study underscores the importance of monitoring and managing ADRs in the development and application of hepatic anti-fibrotic agents to optimize therapeutic strategies for liver fibrosis.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Recent Clinical Trial Failures: Roche, AbbVie, and Cassava Sciences Face Setbacks

Roche's anti-TIGIT drug, tiragolumab, failed to demonstrate a life-extending benefit in a Phase 3 trial for non-small cell lung cancer, raising concerns about the TIGIT inhibitor class.
AbbVie's emraclidine, a muscarinic agonist for schizophrenia acquired from Cerevel Therapeutics, failed in two mid-phase clinical trials, performing no better than placebo.

Prevalence and Profiles of Treatment-Related Adverse Events in Metastatic Breast Cancer Patients Receiving Antibody-Drug Conjugates

A meta-analysis of 23 clinical trials reveals the prevalence and distinct toxicity profiles of treatment-related adverse events (TRAEs) associated with currently approved antibody-drug conjugates (ADCs) for metastatic breast cancer. Gastrointestinal disorders were highly prevalent across all treatments, with Trastuzumab Deruxtecan and Sacituzumab Govitecan showing higher symptom burdens compared to Trastuzumab Emtansine. The study underscores the importance of understanding these TRAEs to enhance supportive care and develop personalized risk-stratified care pathways.

Semaglutide 2.4 mg Shows Promise in MASH Treatment: Phase 3 ESSENCE Trial Results

Semaglutide 2.4 mg demonstrated statistically significant improvements in liver fibrosis and resolution of steatohepatitis in MASH patients compared to placebo.
The ESSENCE trial met its primary endpoints, showing semaglutide's potential to slow MASH progression and reverse existing liver damage.

Avatrombopag Linked to New Adverse Events: FAERS Disproportionality Analysis

A recent study using the FDA Adverse Event Reporting System (FAERS) database has identified new potential adverse events (AEs) associated with avatrombopag.
The analysis revealed previously unreported AEs like liver function abnormalities, photopsia, and ear discomfort, alongside common AEs such as thrombosis and bleeding.

Omaveloxolone's Safety Profile in Friedreich Ataxia: TEAE Analysis from MOXIe Trial

Analysis of the MOXIe trial reveals that most treatment-emergent adverse events (TEAEs) associated with omaveloxolone occurred within the first 12 weeks of treatment.
Elevated aminotransferase levels (AST/ALT) and gastrointestinal disorders were the most frequently observed TEAEs in patients treated with omaveloxolone.

Wegovy Shows Promise in Treating MASH with Advanced Liver Fibrosis

Wegovy (semaglutide) 2.4 mg demonstrated statistically significant superiority over placebo in improving liver histology in patients with MASH and moderate to advanced liver fibrosis.
In the ESSENCE trial, 37% of Wegovy-treated patients showed improvement in liver fibrosis compared to 22.5% in the placebo group after 72 weeks.

Lanifibranor Shows Promise in Phase 3 MASH Trial with Improved Liver Health Biomarkers

Interim analysis of the Phase 3 NATiV3 trial reveals that lanifibranor shows potential in improving liver health in patients with metabolic-associated steatohepatitis (MASH).
The global study, involving 837 participants, assesses lanifibranor's impact on MASH resolution and fibrosis reduction over 72 weeks, with top-line results expected by late 2026.

Aramchol Shows Significant Anti-Fibrotic Effects in MASH Patients, Phase 3 Trial Results Published in Hepatology

Aramchol 300mg BID demonstrates a significant anti-fibrotic effect in patients with metabolic dysfunction-associated steatohepatitis (MASH), as confirmed by multiple objective measurements.
The Phase 3 trial (ARCON) utilized NASH CRN, paired ranked reading, and Artificial Intelligence (AI) quantitative digital analysis to validate the data.

Madrigal's Resmetirom Nears Full Approval for NASH Cirrhosis Treatment Following Phase 3 Enrollment Completion

Madrigal Pharmaceuticals completed patient enrollment for its MAESTRO-NASH OUTCOMES trial, evaluating resmetirom for compensated NASH cirrhosis.
The Phase 3 trial involves 845 patients and aims to measure the progression to liver decompensation events over two to three years.

Real-World Study Highlights Adverse Events Associated with Lenvatinib Use

A comprehensive real-world drug safety surveillance study on lenvatinib has identified significant adverse events (AEs) linked to its use, including immune-mediated hepatitis, portal vein thrombosis, and adrenal insufficiency. The study, analyzing data from 2015 to 2023, found that most AEs occurred within the first month of treatment, with a median onset time of 41 days. Specific targets of lenvatinib, such as FGFR4, PDGFRA, and KIT, were potentially linked to conditions like cholecystitis, cholangitis, and hepatic encephalopathy.

Reference News

[1]
Adverse events of hepatic anti-fibrotic agents in phase 3 and above clinical trials - Frontiers
frontiersin.org · Jan 6, 2025

Study analyzes adverse drug reactions (ADRs) from phase 3 and above clinical trials of hepatic anti-fibrotic agents usin...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy